Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin

被引:42
作者
Larson, Nate [1 ,2 ]
Greish, Khaled [1 ,2 ]
Bauer, Hillevi [1 ,2 ]
Maeda, Hiroshi [4 ]
Ghandehari, Hamidreza [1 ,2 ,3 ]
机构
[1] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84108 USA
[2] Nano Inst Utah, Ctr Nanomed, Salt Lake City, UT 84108 USA
[3] Univ Utah, Dept Bioengn, Salt Lake City, UT 84108 USA
[4] Sojo Univ, Res Inst DDS, Kumamoto 8600082, Japan
基金
美国国家卫生研究院;
关键词
Tanespimycin; 17-AAG; Polymeric micelle; Prostate cancer; DRUG-DELIVERY; MACROMOLECULAR DRUGS; SOLID TUMORS; IN-VITRO; HSP90; GELDANAMYCIN; INHIBITORS; ADVANTAGES; THERAPY; SMANCS;
D O I
10.1016/j.ijpharm.2011.08.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Polymeric micelles carrying the heat shock protein 90 inhibitor tanespimycin (17-N-allylamino-17-demethoxygeldanamycin) were synthesized using poly(styrene-co-maleic acid) (SMA) copolymers and evaluated in vitro and in vivo. SMA-tanespimycin micelles were prepared with a loading efficiency of 93%. The micelles incorporated 25.6% tanespimycin by weight, exhibited a mean diameter of 74 +/- 7 nm by dynamic light scattering and a zeta potential of -35 +/- 3 mV. Tanespimycin was released from the micelles in a controlled manner in vitro, with 62% released in 24h from a pH 7.4 buffer containing bovine serum albumin. The micellar drug delivery systems for tanespimycin showed potent activity against DU145 human prostate cancer cells, with an IC(50) of 230 nM. They further exhibited potent anti-cancer activity in vivo in nu/nu mice bearing subcutaneous DU145 human prostate cancer tumor xenografts, with significantly higher anticancer efficacy as measured by tumor regression when compared to free tanespimycin at an equivalent single dose of 10 mg/kg. These data suggest further investigation of SMA-tanespimycin as a promising agent in the treatment of prostate cancer. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 37 条
[1]   Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies [J].
Banerji, U ;
O'Donnell, A ;
Scurr, M ;
Pacey, S ;
Stapleton, S ;
Asad, Y ;
Simmons, L ;
Maloney, A ;
Raynaud, F ;
Campbell, M ;
Walton, M ;
Lakhani, S ;
Kaye, S ;
Workman, P ;
Judson, I .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4152-4161
[2]   Multifunctional Micellar Nanomedicine for Cancer Therapy [J].
Blanco, Elvin ;
Kessinger, Chase W. ;
Sumer, Baran D. ;
Gao, Jinming .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 234 (02) :123-131
[3]   Biodistribution of HPMA Copolymer-Aminohexylgeldanamycin-RGDfK Conjugates for Prostate Cancer Drug Delivery [J].
Borgman, Mark P. ;
Aras, Omer ;
Geyser-Stoops, Sandra ;
Sausville, Edward A. ;
Ghandehari, Hamidreza .
MOLECULAR PHARMACEUTICS, 2009, 6 (06) :1836-1847
[4]   Hsp90 & Co. - a holding for folding [J].
Buchner, J .
TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (04) :136-141
[5]   17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models [J].
Burger, AM ;
Fiebig, HH ;
Stinson, SF ;
Sausville, EA .
ANTI-CANCER DRUGS, 2004, 15 (04) :377-387
[6]   Rigid interior of styrene-maleic anhydride copolymer aggregates probed by fluorescence spectroscopy [J].
Claracq, J ;
Santos, SFCR ;
Duhamel, J ;
Dumousseaux, C ;
Corpart, JM .
LANGMUIR, 2002, 18 (10) :3829-3835
[7]   Polymeric micelles for drug delivery [J].
Croy, S. R. ;
Kwon, G. S. .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (36) :4669-4684
[8]   In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: Survival improvement and inhibition of liver metastases [J].
Daruwalla, Jurstine ;
Nikfarjam, Mehrdad ;
Greish, Khaled ;
Malcontenti-Wilson, Cathy ;
Muralidharan, Vijayaragavan ;
Christophi, Chris ;
Maeda, Hiroshi .
CANCER SCIENCE, 2010, 101 (08) :1866-1874
[9]   Geldanamycin and its anti-cancer activities [J].
Fukuyo, Yayoi ;
Hunt, Clayton R. ;
Horikoshi, Nobuo .
CANCER LETTERS, 2010, 290 (01) :24-35
[10]   Block copolymer micelles: preparation, characterization and application in drug delivery [J].
Gaucher, G ;
Dufresne, MH ;
Sant, VP ;
Kang, N ;
Maysinger, D ;
Leroux, JC .
JOURNAL OF CONTROLLED RELEASE, 2005, 109 (1-3) :169-188